Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 0 of 1 range targets
Below the range 0 below the last range given

The numbers BCRX said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $625.00M to $645.00M release Jan 12, 2026
Kept $625.00M to $645.00M release Feb 26, 2026
Kept $625.00M to $645.00M release May 6, 2026
Kept $625.00M to $645.00M release Aug 5, 2026
Kept $625.00M to $645.00M release Nov 4, 2026
– Not reported yet
The company's words
–ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– release Jan 12, 2026
—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— release Feb 26, 2026
The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB (peramivir injection), to be between $635 million and $660 million. release May 6, 2026
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — release Aug 5, 2026
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — release Nov 4, 2026
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $380.00M to $400.00M release Jan 8, 2024
Kept $380.00M to $400.00M release Feb 26, 2024
Raised $390.00M to $400.00M release May 6, 2024
Raised $420.00M to $435.00M release Aug 5, 2024
Raised $443.00M to $448.00M release Nov 4, 2024
$450.71M
10-K filed 2025-02-25
Above the range
The company's words
—ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— release Jan 8, 2024
—2024 ORLADEYO net revenue expected to be between $380-$400 million— release Feb 26, 2024
Based on the team’s success in accelerating ORLADEYO patients through the U.S. reauthorization process faster than anticipated, the company is adjusting its outlook for full year 2024 global net ORLADEYO revenue to be between $390 million and $400 million, the top end of its prior guidance range. release May 6, 2024
—Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— release Aug 5, 2024
— Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — release Nov 4, 2024
Revenue (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $390.00M to $400.00M release May 6, 2024
Raised $430.00M to $435.00M release Nov 4, 2024
– No standard number
The company's words
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — release May 6, 2024
— Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — release Nov 4, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Revenue, Fiscal 2025 (ended Dec 31, 2025): said $590.00M to $600.00M, reported $874.84M. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (16 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.